Literature DB >> 23223433

The role of B7 family molecules in hematologic malignancy.

Paul Greaves1, John G Gribben.   

Abstract

The B7 family consists of structurally related, cell-surface proteins that regulate immune responses by delivering costimulatory or coinhibitory signals through their ligands. Eight family members have been identified to date including CD80 (B7-1), CD86 (B7-2), CD274 (programmed cell death-1 ligand [PD-L1]), CD273 (programmed cell death-2 ligand [PD-L2]), CD275 (inducible costimulator ligand [ICOS-L]), CD276 (B7-H3), B7-H4, and B7-H6. B7 ligands are expressed on both lymphoid and nonlymphoid tissues. The importance of the B7 family in regulating immune responses is clear from their demonstrated role in the development of immunodeficiency and autoimmune diseases. Manipulation of the signals delivered by B7 ligands shows great potential in the treatment of cancers including leukemias and lymphomas and in regulating allogeneic T-cell responses after stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23223433      PMCID: PMC3563361          DOI: 10.1182/blood-2012-10-385591

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  197 in total

1.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

2.  Transplantation of anergic histoincompatible bone marrow allografts.

Authors:  E C Guinan; V A Boussiotis; D Neuberg; L L Brennan; N Hirano; L M Nadler; J G Gribben
Journal:  N Engl J Med       Date:  1999-06-03       Impact factor: 91.245

3.  Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Authors:  Edward Y Woo; Heidi Yeh; Christina S Chu; Katia Schlienger; Richard G Carroll; James L Riley; Larry R Kaiser; Carl H June
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

4.  Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.

Authors:  J L Schultze; A A Cardoso; G J Freeman; M J Seamon; J Daley; G S Pinkus; J G Gribben; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

5.  Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage.

Authors:  Taishi Yamashita; Hideto Tamura; Chikako Satoh; Eiji Shinya; Hidemi Takahashi; Lieping Chen; Asaka Kondo; Takashi Tsuji; Kazuo Dan; Kiyoyuki Ogata
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

6.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

Authors:  G J Freeman; J G Gribben; V A Boussiotis; J W Ng; V A Restivo; L A Lombard; G S Gray; L M Nadler
Journal:  Science       Date:  1993-11-05       Impact factor: 47.728

7.  Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.

Authors:  Bruce R Blazar; Beatriz M Carreno; Angela Panoskaltsis-Mortari; Laura Carter; Yoshiko Iwai; Hideo Yagita; Hiroyuki Nishimura; Patricia A Taylor
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

8.  Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.

Authors:  P S Linsley; P M Wallace; J Johnson; M G Gibson; J L Greene; J A Ledbetter; C Singh; M A Tepper
Journal:  Science       Date:  1992-08-07       Impact factor: 47.728

9.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.

Authors:  P S Linsley; W Brady; L Grosmaire; A Aruffo; N K Damle; J A Ledbetter
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

10.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

View more
  77 in total

1.  Recurrent activating mutations of CD28 in peripheral T-cell lymphomas.

Authors:  J Rohr; S Guo; J Huo; A Bouska; C Lachel; Y Li; P D Simone; W Zhang; Q Gong; C Wang; A Cannon; T Heavican; A Mottok; S Hung; A Rosenwald; R Gascoyne; K Fu; T C Greiner; D D Weisenburger; J M Vose; L M Staudt; W Xiao; G E O Borgstahl; S Davis; C Steidl; T McKeithan; J Iqbal; W C Chan
Journal:  Leukemia       Date:  2015-12-31       Impact factor: 11.528

2.  Effect of Chronic Uremia on the Cell Surface Expression of B7 Family Costimulatory Molecules in an HLA-A2 Transgenic Mouse Model of Chronic Kidney Disease.

Authors:  Paul E Makidon; Douglas M Smith; Jeffery V Groom Ii; Zhengyi Cao; Jeffery J Landers; James R Baker
Journal:  Comp Med       Date:  2015-08       Impact factor: 0.982

3.  Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway.

Authors:  S M Ahmad; S K Larsen; I M Svane; M H Andersen
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

4.  Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.

Authors:  Mads Hald Andersen
Journal:  J Natl Cancer Inst       Date:  2015-06-10       Impact factor: 13.506

5.  Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.

Authors:  Güllü Görgün; Mehmet K Samur; Kristen B Cowens; Steven Paula; Giada Bianchi; Julie E Anderson; Randie E White; Ahaana Singh; Hiroto Ohguchi; Rikio Suzuki; Shohei Kikuchi; Takeshi Harada; Teru Hideshima; Yu-Tzu Tai; Jacob P Laubach; Noopur Raje; Florence Magrangeas; Stephane Minvielle; Herve Avet-Loiseau; Nikhil C Munshi; David M Dorfman; Paul G Richardson; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

6.  CD86 polymorphism affects pneumonia-induced sepsis by decreasing gene expression in monocytes.

Authors:  Haihan Song; Lunxian Tang; Mingzheng Xu; Hongqiang Li; Shumin Xu; Guanggang Li; Xiaowei Bao; Bingke Sun; Tingting Cheng; Qian Yang; Jianwen Bai
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

7.  Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner.

Authors:  Qian Zhang; Hong Yi Wang; Fang Wei; Xiaobin Liu; Jennifer C Paterson; Darshan Roy; Daniela Mihova; Anders Woetmann; Andrzej Ptasznik; Niels Odum; Stephen J Schuster; Teresa Marafioti; James L Riley; Mariusz A Wasik
Journal:  J Immunol       Date:  2014-02-12       Impact factor: 5.422

8.  CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.

Authors:  Hadas Lewinsky; Avital F Barak; Victoria Huber; Matthias P Kramer; Lihi Radomir; Lital Sever; Irit Orr; Vita Mirkin; Nili Dezorella; Mika Shapiro; Yosef Cohen; Lev Shvidel; Martina Seiffert; Yair Herishanu; Shirly Becker-Herman; Idit Shachar
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

Review 9.  Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Authors:  Fabienne McClanahan; Thomas G Sharp; John G Gribben
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

10.  Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.

Authors:  Zhenyu Xu; Jing Shen; Maggie Haitian Wang; Tao Yi; Yangyang Yu; Yinxin Zhu; Bo Chen; Jianping Chen; Longfei Li; Minxing Li; Jian Zuo; Hui Jiang; Dexi Zhou; Jiajie Luan; Zhangang Xiao
Journal:  Oncoimmunology       Date:  2016-07-11       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.